Single-nucleotide polymorphism

Argonne Uncovers Insights About Prostate Cancer Risk and Genetic Ancestry

Retrieved on: 
Thursday, February 15, 2024

A recent study involving scientists from the U.S. Department of Energy’s (DOE) Argonne National Laboratory has uncovered insights into the prostate cancer risks of people from a variety of genetic ancestries.

Key Points: 
  • A recent study involving scientists from the U.S. Department of Energy’s (DOE) Argonne National Laboratory has uncovered insights into the prostate cancer risks of people from a variety of genetic ancestries.
  • Prostate cancer is the most frequently diagnosed non-skin cancer globally, and as such, it is a problem that affects the entire human population.
  • To understand the likelihood of an individual or population developing prostate cancer, researchers create what is known as a Genetic Risk Score (GRS).
  • This work was centered around a desire to understand the genetic makeup that increases risks for diseases like prostate cancer.

HKG epiTherapeutics Limited Announces the Launch of its MetaGen Mutations Panel

Retrieved on: 
Wednesday, January 31, 2024

HONG KONG, Jan. 31, 2024 /PRNewswire/ -- HKG epiTherapeutics Limited ("HKG" or "the Company"), a commercial-stage biotech company developing novel tools for the early detection of cancer and promoting healthy aging, announced today the launch of its new product, MetaGen Mutations Panel, an innovative genetic methylation test, which evaluates specific genes that offer individuals unparalleled insights into their genetic profiles and their effects on health and aging.

Key Points: 
  • These genes play a key role in the body's methylation processes, influencing a wide array of biological functions – from DNA methylation and repair and detoxification – to neurotransmitter synthesis.
  • "The launch of our MetaGen Mutations Panel is a true testament to HKG's commitment to empowering individuals with detailed health insights, enabling informed decisions about nutrition, lifestyle and health management strategies," said Prof. Szyf, HKG's Founder and CEO.
  • The launch of this new product marks a significant step towards this goal, offering a holistic and scientifically grounded tool for personalized health."
  • The MetaGen Mutations Panel is now available for purchase online, shipped directly to customers for easy access to health insights.

Advaita Bio awarded $1.7 million NIH study to pioneer platform for the analysis of single-cell data

Retrieved on: 
Tuesday, January 30, 2024

ANN ARBOR, Mich., Jan. 30, 2024 /PRNewswire-PRWeb/ -- Advaita Bio was awarded $1.7 million from the National Institute of Health (NIH) to develop a new platform for the analysis of single-cell data. AdvaitaBio is the leader in the interpretation of high-throughput biomedical data including variant interpretation, pathway analysis, disease subtype discovery, single cell analysis, and integration across multiple data types. This research will develop advanced methods for the analysis of single cell and spatial genomics and transcriptomics data.

Key Points: 
  • ANN ARBOR, Mich., Jan. 30, 2024 /PRNewswire-PRWeb/ -- Advaita Bio was awarded $1.7 million from the National Institute of Health (NIH) to develop a new platform for the analysis of single-cell data.
  • AdvaitaBio is the leader in the interpretation of high-throughput biomedical data including variant interpretation, pathway analysis, disease subtype discovery, single cell analysis, and integration across multiple data types.
  • This research will develop advanced methods for the analysis of single cell and spatial genomics and transcriptomics data.
  • Advaita's Life Scientist and Principal Investigator, Cristiana Iosef, DVM, PhD, explains, "The world of single cell analysis is currently a jungle.

Next-gen Sequencing and Genomic Analysis Advancements Report 2024 - Enabling Precision Medicine through High-precision Sequencing Approaches

Retrieved on: 
Thursday, January 18, 2024

DUBLIN, Jan. 18, 2024 /PRNewswire/ -- The "Advancements in Next-gen Sequencing and Genomic Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 18, 2024 /PRNewswire/ -- The "Advancements in Next-gen Sequencing and Genomic Analysis" report has been added to ResearchAndMarkets.com's offering.
  • From Sanger sequencing to next-generation sequencing, technologies and chemistries have improved/advanced to reduce costs and ensure faster timelines.
  • Developments in NGS chemistries such as single-molecule real-time sequencing, sequencing by synthesis, nanopore sequencing, ion and semiconductor technology, in addition to miniaturization of sequencing instrumentation and automation of NGS, boost the adoption of NGS across biological labs.
  • Technological advancement of AI-/ML-powered platforms for analyzing sequencing data is helping analyze and interpret large volumes of sequencing data within hours.

The World Market for Molecular Diagnostics 12th Edition, Featuring Competitive Analysis of Advanced Cell Diagnostics, Berry Genomics, Biocartis, bioMerieux, CareDx, Danaher, Hologic, Illumina & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024

Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.

Key Points: 
  • Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.
  • This new report reveals that post-pandemic the market remains ripe with opportunity, notably in the areas of infectious diseases, cancer, and transplant diagnostics.
  • Molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare.
  • This report evaluates the present configuration of the molecular diagnostics market in cancer, providing insights into prominent products and geographical segmentation.

DNA Labs International solves significant cold cases with QIAGEN workflow for forensic genetic genealogy

Retrieved on: 
Thursday, November 30, 2023

Venlo, the Netherlands, and Deerfield Beach, Florida, Nov. 30, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DNA Labs International announced today that DLI has recently solved two decades-old “cold cases” using QIAGEN solutions.

Key Points: 
  • Venlo, the Netherlands, and Deerfield Beach, Florida, Nov. 30, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DNA Labs International announced today that DLI has recently solved two decades-old “cold cases” using QIAGEN solutions.
  • By utilizing QIAGEN’s ForenSeq Kintelligence Kit for forensic investigative genetic genealogy (FIGG) to sequence targeted DNA regions, a profile suitable for genealogy research was produced.
  • Rachel Oefelein, Chief Scientific Officer at DNA Labs International, stated: “Our mission at DNA Labs International is to help law enforcement provide justice and answers to the families and victims of crime.
  • “We are honored to collaborate with partners like DNA Labs International, who expertly leverage our workflow to work with authorities to deliver justice for victims of crime and their families.”
    DLI has used forensic genetic genealogy to help solve many other cases.

SNP Therapeutics Launches Genate™: The First Gene-Guided Precision Nutrition Solution for the Prenatal Market

Retrieved on: 
Tuesday, December 19, 2023

Genate Prenatal Nutrition will enable women to optimize their nutrition plan based on gene variants associated with nutrient metabolism.

Key Points: 
  • Genate Prenatal Nutrition will enable women to optimize their nutrition plan based on gene variants associated with nutrient metabolism.
  • "We developed Genate Prenatal Nutrition because nutritional needs during pregnancy can vary significantly from one woman to another," said Jon Kleu, CEO of SNP Therapeutics.
  • With the Genate Prenatal Genetic Test and new Genate nutrition line, women have powerful new tools to help them support their pregnancy nutrition plans."
  • Genate Nutrition starts with the Essential Prenatal Nutrition dietary supplement, designed to provide women with a comprehensive base formulation.

Take Control of Your Health in the New Year with Functional Wellness Tests from Designs for Health

Retrieved on: 
Thursday, December 14, 2023

PALM COAST, Fla., Dec. 14, 2023 /PRNewswire/ -- As we gear up for the New Year, Designs for Health, the expert-recommended and preferred brand for high-quality, professional strength, research-backed supplements is making it easier than ever for healthcare practitioners to provide a personalized approach to patient outcomes thanks to its innovative Spotlight functional wellness tests. The three tests, Metabolomics Spotlight, GI Spotlight, and Genomic Spotlight, help inform and guide healthcare practitioners to support their patients' overall optimal health through appropriate diet, lifestyle, and nutraceutical suggestions by assessing their metabolic status, microbiome, or genomic data.

Key Points: 
  • Designs for Health GI Spotlight™ provides an in-depth look into the symbiotic health status of the gut microbiome.
  • It then evaluates eight key areas of health including cellular communication, bone and structural health, cognitive health, detoxification, endocrine health, inflammatory status, GI health, and aging.
  • Designs for Health Spotlight™ testing must be ordered or authorized by a qualified healthcare provider registered with Designs for Health.
  • Designs for Health Spotlight™ tests are not diagnostic and are not eligible for coverage under Medicare, Medicaid, or medical insurance.

Mark Farrah Associates Assessed the 2024 Competitive Medicare Advantage Market

Retrieved on: 
Monday, October 30, 2023

Mark Farrah Associates (MFA), www.markfarrah.com , released an analysis presenting a brief assessment of the 2024 Medicare market landscape.

Key Points: 
  • Mark Farrah Associates (MFA), www.markfarrah.com , released an analysis presenting a brief assessment of the 2024 Medicare market landscape.
  • With the 2024 Annual Election Period (AEP) well underway, health plans invested in Medicare Advantage (MA) business have been eagerly marketing their products to attract more seniors.
  • MFA reported 5,805 distinct MA plan offerings are in the market lineup for the current 2024 AEP.
  • This includes MA plans, Medicare Advantage with prescription drug plans (MAPDs), Medicare/Medicaid plans (MMPs), and Special Needs Plans (SNPs).

Eutelsat Group Announces Ambitious Targets to Reduce Its Carbon Impact and Fight Climate Change

Retrieved on: 
Thursday, October 19, 2023

By 2030, the Group is committed to reducing its energy-related greenhouse gas (GHG) emissions (Scopes 1+2) by 50% compared to the 2021 baseline year.

Key Points: 
  • By 2030, the Group is committed to reducing its energy-related greenhouse gas (GHG) emissions (Scopes 1+2) by 50% compared to the 2021 baseline year.
  • Since 2021 the Group has been reporting its full Scope 3 emissions, including the impact of the geostationary satellite fleet (GEO).
  • This holistic approach reflects the Group’s dedication to understanding its carbon footprint, enhancing its sustainability efforts and contributing to the global fight against climate change.
  • “In a world marked by critical environmental challenges, Eutelsat Group is dedicated to implementing ambitious measures to reduce its energy-related emissions and safeguard the environment, both on Earth and in space.